A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM.
Giaccone G, et al. Among authors: van der vliet hj, van den eertwegh aj.
Clin Cancer Res. 2002 Dec;8(12):3702-9.
Clin Cancer Res. 2002.
PMID: 12473579
Clinical Trial.